Joining the flock of biotechs headed to Oyster Point, gene therapy company Sangamo Therapeutics is building a new headquarters and manufacturing facility in the Bay Area development.
The new site will be 88,000 square-feet of space at 7000 Marina Boulevard. It will include laboratories, workstations, collaborative space, and a large-scale manufacturing facility to make Sangamo’s genomic therapies.
Sandy Macrae, Sangamo’s CEO, told investors in an earnings call that the new space will help the company attract talent.
“It will importantly provide us a more competitive location and workspace as we recruit the managerial, clinical, operational and manufacturing talent, we need to achieve our long-term goals,” Macrae said.
In biopharma, giants and startups alike are finding trophy locations like Oyster Point irresistible as they suck in tons of new talent. Last year, AstraZeneca announced a 230,000 square-foot project at The Cove at Oyster Point, joining Genentech and hundreds of biotechs sprawling on the new campus while under construction.
Sangamo expects to open the new facility in early 2018. The company is keeping its facility in Point Richmond and turning it into a R&D center, the company said.
“We intend to remain a top employer of scientists in the East Bay and are planning to update our Point Richmond facility as a Research Center for Sangamo,” Macrae said in a statement.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription